TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) (1.1) As monotherapy for the treatment of patients with relapsing forms of multiple
TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [see Warnings and Precautions (5.1)]. When initiating and continuing treatment with TYSABRI ...
TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical...
TYSABRI® (natalizumab) | Official Patient Website
TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).
TYSABRI is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease despite a full and adequate course of treatment with at least
TOUCHTM is a distribution program designed to assess the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI®, minimize the risk of PML, minimize death and disability...
TYSABRI (Biogen Inc.): FDA Package Insert - MedLibrary.org
2024年10月24日 · TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [see Warnings and Precautions (5.1) ].
TYSABRI® (natalizumab) is a recombinant humanized IgG4κ monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the...
Tysabri 300 mg is administered by intravenous infusion once every 4 weeks. Continued therapy must be carefully reconsidered in patients who show no evidence of therapeutic benefit beyond 6 months. Data on the safety and efficacy of natalizumab at 2 years were generated from controlled, double– blind studies.
TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis. Safety and efficacy in patients …
- 某些结果已被删除